智通财经APP获悉，宜明昂科-B(01541)午后涨超5%，截至发稿，涨3.13%，报5.61港元，成交额6643.18万港元。
消息面上，宜明昂科近日发布公告，宣布公司已获中国国家药监局批准进行IMM0306用于治疗狼疮性肾炎的II期临床试验。IMM0306是一种靶向CD47和CD20的双特异性抗体，具有全球首个进入临床阶段的CD47和CD20双靶向特性。
据悉，IMM0306是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子，公司拥有其全球知识产权及商业化权利。太平洋证券研报预测，IMM0306远期销售峰值有望达到10.8亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.